XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value
Note 19 - Fair Value
Fair value is defined as the price that would be expected to be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The FASB provides accounting rules that classify the inputs used to measure fair value into the following hierarchy:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 – Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.
Level 3 – Unobservable inputs for the asset or liability.

The following tables present the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022:
 March 31, 2023
 TotalLevel 1Level 2Level 3
Assets:
Cash and cash equivalents$295.3 $294.5 $0.8 $ 
Cash and cash equivalents measured at net asset value35.2 
Restricted cash8.6 8.6   
Short-term investments38.6  38.6  
Interest rate swap contract2.1  2.1  
Foreign currency forward contracts3.0  3.0  
     Total assets$382.8 $303.1 $44.5 $ 
Liabilities:
Foreign currency forward contracts$23.1 $ $23.1 $ 
     Total liabilities$23.1 $ $23.1 $ 
 December 31, 2022
 TotalLevel 1Level 2Level 3
Assets:
Cash and cash equivalents$292.1 $289.3 $2.8 $— 
Cash and cash equivalents measured at net asset value39.5 
Restricted cash9.1 9.1 — — 
Short-term investments39.2 — 39.2 — 
Interest rate swap contract3.1 — 3.1— 
Foreign currency forward contracts4.5 — 4.5 — 
     Total assets$387.5 $298.4 $49.6 $— 
Liabilities:
Foreign currency forward contracts$19.8 $— $19.8 $— 
     Total liabilities$19.8 $— $19.8 $— 
Cash and cash equivalents are highly liquid investments with maturities of three months or less when purchased and are valued at the redemption value. Short-term investments are investments with maturities between four months and one year, and generally are valued at amortized cost, which approximates fair value. A portion of the cash and cash equivalents and short-term investments are valued based on net asset value. The Company uses publicly available market interest rates to measure the fair value of its interest rate swap contracts. The Company uses publicly available foreign currency forward and spot rates to measure the fair value of its foreign currency forward contracts.
Note 19 - Fair Value (continued)
In addition, the Company remeasures certain assets at fair value, using Level 3 inputs, as a result of the occurrence of triggering events such as purchase accounting for acquisitions or goodwill impairment.
No other material assets were measured at fair value on a nonrecurring basis during the three months ended March 31, 2023 and 2022, respectively.
Financial Instruments:
The Company’s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, trade accounts payable, short-term borrowings and long-term debt. Due to their short-term nature, the carrying value of cash and cash equivalents, short-term investments, accounts receivable, trade accounts payable and short-term borrowings are a reasonable estimate of their fair value. Due to the nature of fair value calculations for variable-rate debt, the carrying value of the Company's long-term variable-rate debt is a reasonable estimate of its fair value. The fair value of the Company’s long-term fixed-rate debt, based on quoted market prices, was $1,381.7 million and $1,353.5 million at March 31, 2023 and December 31, 2022, respectively. The carrying value of this debt was $1,420.3 million and $1,417.9 million at March 31, 2023 and December 31, 2022, respectively. The fair value of long-term fixed-rate debt was measured using Level 2 inputs.
The Company does not believe it has significant concentrations of risk associated with the counterparties to its financial instruments.